You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020161019
Dec 20208208
Jan 20213104
Feb 20213202
Mar 20217506
Apr 20215108
May 202132010
Jun 2021309
Jul 20210014
Aug 2021307
Sep 20212056
Oct 202194055
Nov 2021112025
Dec 20213600
Jan 20229109
Feb 202267010
Mar 202298014
Apr 2022149014
May 202296016
Jun 2022123017
Jul 202277012
Aug 202294012
Sep 202285015
Oct 2022132018
Nov 202211909
Dec 20229809
Jan 2023174017
Feb 2023180031
Mar 2023126015
Apr 202384015
May 2023166018
Jun 2023110013
Jul 202396014
Aug 2023148010
Sep 20236204
Oct 20238409
Nov 202314207
Dec 20238206
Jan 20243004
Feb 20244407
Mar 2024108035
Apr 202489020
May 202490020
Jun 202497010
Jul 202410809
Aug 202413707
Sep 20247208
Oct 2024118010
Nov 202410406
Dec 2024116013
Jan 202570013
Feb 202526015
Mar 20250015
Apr 20250010
May 20250010
Jun 2025108
Total46070757